MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


RNS News Service

I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.

Further re. Conditional Sale of Pharm2Farm holding

RNS

RNS Number : 5035C
Braveheart Investment Group plc
19 October 2020
 

19 October 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Further re. Conditional Sale of Pharm 2 Farm Limited holding

On 21 August 2020, Braveheart announced the conditional sale its 51.72% holding in Pharm 2 Farm Limited ("P2F") to Remote Monitored Systems plc ("RMS") for a consideration of 310,354,815 new Ordinary Shares of 0.2p each in RMS ("RMS Shares") ("Consideration Shares") ("P2F Sale") .

The P2F sale is conditional, among other things, on the Takeover Panel granting a waiver of the Rule 9 obligations arising out of the P2F Sale and the independent shareholders of RMS approving the whitewash of Braveheart's Rule 9 obligations at a general meeting.

RMS announced earlier today that a shareholder circular (the "   RMS   Circular   ") will be published today that contains information relating to the P2F Sale and includes a notice convening a general meeting of RMS (the "   RMS   General Meeting   "). The RMS General Meeting will be held at 10:30 a.m. on 4 November 2020 . The RMS Circular is expected to be posted to RMS Shareholders shortly.

The P2F Sale is expected to be completed on 5 November 2020, subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the   independent shareholders of RMS, at the RMS General Meeting.

A further announcement will be made in due course.

For further information: 



Braveheart Investment Group plc

Tel: 01738 587555

Trevor Brown CEO




Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

David Worlidge / James Hornigold




Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Heena Karani / Lucy Williams


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURMLBBTMTJBBPM